NEO100 for recurrent or progressive high-grade meningioma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies NEO100, a treatment for adults and children (age 12+) with Grade II or III meningioma that has come back or kept growing after surgery and radiation. It may help shrink tumors or slow growth when standard options have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your meningioma must be Grade II or Grade III (proven by lab tissue testing).
- Your tumor must still be measurable and either be left over, growing, or returning after surgery and radiation (metastasis is allowed).
- You must have finished surgery and radiation far enough in advance and still show tumor activity after radiation.
- You must be able to take part safely: steroid dose must be stable/decreasing, side effects from prior treatment must be mild, and you must meet blood/organ test limits.
- You must be at least 12 years old and well enough to do daily activities (ECOG 0–2 or KPS 60+), and expected to live at least 3 months.
- You must agree to frequent visits and blood draws, and—if pregnancy is possible—use reliable birth control and not breastfeed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
This trial tests a new drug called SYHA1813 for people with high-grade meningioma that has come back or is growing despite previous treatment. The goal is to see if the drug can shrink or slow down the tumor.
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
This trial tests a new drug called SYHA1813 for meningiomas (tumors in the brain's protective lining) that have come back or are growing after surgery and radiation. The goal is to see if this drug can help slow or stop tumor growth.
Hear when a new Residual, Progressive or Recurrent Grade II or III Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.